

IDERA PHARMACEUTICALS, INC.

Form 8-K

June 08, 2006

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 7, 2006**

IDERA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction
of Incorporation)

001-31918

(Commission File Number)

04-3072298

(IRS Employer
Identification No.)

**345 Vassar Street,
Cambridge, Massachusetts**

(Address of Principal Executive Offices)

02139

(Zip Code)

(617) 679-5500

Registrant's telephone number, including area code:

n/a

(Former Name or Former Address, if Changed Since Last
Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 1.01. Entry into a Material Definitive Agreement.

SIGNATURE

Table of Contents

Item 1.01. Entry into a Material Definitive Agreement.

On June 7, 2006, at the 2006 annual meeting of stockholders of Idera Pharmaceuticals, Inc. (the Registrant), the Registrant's stockholders approved an amendment to the Registrant's 2005 Stock Incentive Plan increasing the number of shares of the Registrant's common stock issuable under that plan from 5,000,000 to 9,000,000 and an amendment to the Registrant's 1995 Employee Stock Purchase Plan increasing the number of shares of the Registrant's common stock issuable under that plan from 500,000 to 1,000,000. These amendments became effective upon stockholder approval.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDERA PHARMACEUTICALS, INC.

Date: June 8, 2006

By: /s/ Robert G. Andersen
Robert G. Andersen
Chief Financial Officer and Vice
President of Operations